Benzinga - During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Here's a look at the most recent high-yield dividend stock ratings from the most accurate Wall Street analysts, according to Benzinga's Analyst Stock Ratings.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
Omega Healthcare Investors, Inc. (NYSE: OHI)
- Dividend Yield: 10%
- Citigroup analyst Nicholas Joseph maintained a Neutral rating and cut the price target from $30 to $28 on Feb. 22, 2023. This analyst has an accuracy rate of 67%.
- Raymond James analyst Jonathan Hughes maintained an Outperform rating and cut the price target from $35 to $33 on Feb. 15, 2023. This analyst has an accuracy rate of 67%.
- Recent News: Omega Healthcare reported a drop in earnings for the fourth quarter.
- Dividend Yield: 9.56%
- Citigroup analyst Nicholas Joseph maintained a Sell rating and raised the price target from $30 to $35 on Feb. 8, 2023. This analyst has an accuracy rate of 67%.
- Baird analyst David Rodgers maintained a Neutral rating and increased the price target from $38 to $43 on Jan. 30, 2023. This analyst has an accuracy rate of 66%.
- Recent News: SL Green Realty reported worse-than-expected Q4 sales results.
- Dividend Yield: 8.08%
- Raymond James analyst RJ Milligan maintained a Strong Buy rating and cut the price target from $48 to $45 on Jan. 9, 2023. This analyst has an accuracy rate of 66%.
- JP Morgan analyst Anthony Paolone upgraded the stock from Underweight to Neutral with a price target of $52 on Dec. 16, 2022. This analyst has an accuracy rate of 73%.
- Recent News: The company reported better-than-expected sales for its fourth quarter.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.